PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1

IntroductionImmunotherapy, especially immune checkpoint blockade (ICB), holds promise as a therapeutic strategy in colorectal cancer (CRC) by harnessing the patient’s immune system to target malignant cells. Particularly, the PD-1/PD-L1 axis is widely recognized for its critical role in tumor microe...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Lvyun Zhu, Ying Qu, Junru Yang, Tong Shao, Jingyu Kuang, Chuanyang Liu, Yanhua Qi, Ming Li, Yingying Li, Sujuan Zhang, Jingyang Wang, Yu Liu, Jiali Liu, Yanming Hu, Lingyun Zhu, Tao Hou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-12-01
Subjects:	immune checkpoint blockade colorectal cancer antitumor immunity therapeutic target tumor microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1486888/full